Indianpharmanetwork11 Dec, 2022Health
The medicine, Blincyto, contains Blinatumomab as an active ingredient with inactive ingredients citric acid monohydrate, lysine hydrochloride, polysorbate 80, trehalose dihydrate, and sodium hydroxide. Blinatumomab is a bispecific CD19-directed CD3 T-cell engager that binds to CD19 (expressed on cells of B-lineage origin) and CD3 (expressed on T cells).
Healthworx, Llc
A Way To Makkah Umrah Services
Maruti Suzuki
Reliable Storage System
Luxautic Car Rental
Winairlines Portugal
Blackcruise
Ug78
F168
Top Interior Fit Out Companies In Dubai